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Aim: To evaluate the dual inhibitory effect of epigallocatechin gallate on Alzheimer’s pathogenesis. 
Methods: Cholinesterase inhibition studies were performed by kinetic Ellman methods and also the inhibitory 
effect of molecule on amyloid fibrillation is determined by dye binding thioflavin T method. 
Results: Epigallocatechin gallate inhibited both types of cholinesterases and amyloid fibrillation. The 
inhibition of acetylcholinesterase indicated an uncompetitive inhibition whereas butyrylcholinesterase 
inhibition had an unique pattern. Compound inhibited butyrylcholinesterase with two types of inhibition in a 
dose related manner. Fibrillation destabilization is also observed by the compound. 
Conclusion: Our results indicated that epigallocatechin gallate may be accepted as a candidate molecule as 
the dual effective drugs for neurodegenerative diseases. 
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Introduction 
Catechins are polyphenols that belong to plant-
derived flavonoid family. Antioxidant effects 
are the well-known effects and their prooxidant 
behavior is also reported depending on the dose 
and route of administration [1,2]. Dietary 
sources, tea and especially green tea is a 
fundamental source of catechins for human. 
The major active component   of the 
polyphenolic content of green tea is 
epigallocatechin gallate (EGCG).  Besides 
antioxidant effects, some other beneficial roles 
of EGCG are reported as antiatherogenic, 
anticarcinogenic, antiapoptotic and its 
importance in neurodegenerative diseases is 
widely emphasized in experimental in vivo 
studies [3,4]. Many studies of human clinical 
trials showed to have an augmented healing 
effect on the cognitive dysfunction by the use 
of flavanol compounds. 
Alzheimer’s disease (AD) is a deteriorative 
neurological disorder characterized by loss of 
memory and mental functions, behavioral 
disorders and also impairment of cholinergic 
neurotransmission. Although the etiology of 
AD is not clarified definitely yet, there are some 
well accepted features about the basis of 
disease. Aggregation of amyloid peptides is 
reported as the most common reason in the 
onset and progression. Amyloid peptides are 
the proteolytic cleavage products of amyloid 
precursor protein (APP). Although this 
cleavage is a physiological process, the activity 
of specific enzymes results with the formation 
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of fragments (amyloid beta 1-40, amyloid beta 
1-42) that form toxic aggregates (amyloid 
plaques) in the brain. The inhibition of 
aggregation is accepted as the main strategy for 
the treatment of the disease and there are 
several in vitro reports dealing with this 
approach [5-9]. 
Another well-known fact about the pathology 
and progress of the AD is the attenuation of 
cholinergic response. Whether it is caused by 
the apoptosis of cholinergic neurons or the 
decreased activity of acetylcholinesterase; it is 
mainly reported that the diminished 
acetylcholine levels has an important role in the 
severe symptoms of AD. Cholinesterase 
inhibitors are widely used medications to 
overcome this problem on the symptomatic 
treatment of the disease for an improved quality 
of lifetime. Cholinesterases are the serine 
hydrolases responsible for the cholinergic 
metabolism. Acetylcholinesterase (AChE; 
E.C.3.1.1.7) and butyrylcholinesterase (BChE; 
E.C.3.1.1.8) may use acetylcholine as the 
substrate with different affinities and both 
known to have roles in the maintanance of 
acetylcholine levels. Besides the enzymatic 
activity, many in vitro studies report another 
function of AChE in the molecular pathology of 
AD. Experiments show that, the peripheral 
anionic site (PAS) of the AChE interacts with 
amyloid peptides behaving as a core for   
promoting fibril aggregation [10].  
Upon these observations experiments mainly 
focus on the generation and development of the 
dual effective cholinesterase inhibitors that 
target both the enzymatic activity and self-
fibrillation [11,12].   
There are several reports dealing with the 
inhibitory effects of flavonoids on the 
cholinesterases [13]. Our study is aimed to 
determine the inhibitory parameters of EGCG 
on cholinesterases and to evaluate the possible 
destabilization of amyloidogenesis within the 
determined pharmacological concentrations 
obtained by kinetic analysis. Based on our 
hypothesis EGCG may be nominated as a 
member of dual effective drugs family for 
Alzheimer’s treatment.   
 
Materials and methods 
 
Chemicals 
Human recombinant AChE, Equine serum 
BChE, amyloid peptides 1-40/1-42, 
epigallocatechin-3-gallate (EGCG), 
acetylthiocholineiodide (ATCh), 
butyrylthiocholineiodide (BTCh) and 
Thioflavin T (ThT) were purchased from 
Sigma–Aldrich (MO, USA).  All biochemical 
studies were performed in triplicate and data 
were expressed as mean ± SEM. 
 
Enzymatic Analysis 
Enzyme activities (AChE and BChE) were 
assayed by the Ellman Method with/without 
various concentrations of inhibitor (EGCG). 
The tubes having zero concentrations of EGCG 
are used as the control.  The activity medium 
was containing 100 mM MOPS pH 8.0, 0.05–
0.5 mM ATCh or BTCh   as the substrate, 0.125 
mM dithiobisnitrobenzoic acid (DTNB) and 
inhibitor. Reactions were initiated by the 
addition of enzyme(s) (0.02 U/mL) and the 
absorbance change at 412 nm was monitored 
spectrophotometrically against the sample 
blank (Shimadzu-1601, Japan) at 25 °C [14]. 
 
Amyloid peptide fibrillation  
The inhibitory effect of EGCG on the amyloid 
aggregation is tested by Thioflavin T 
fluorescence method.  ThT is a dye giving a 
characteristic fluorescence upon binding to 
peptides/polypeptides and also aggregates [15]. 
Due to characteristics of the binding, the 
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increase in the fluorescence with respect to 
control, is accepted as the increase of 
fibrillation (aggregation). Commercially 
available peptides were dissolved in 100 mM 
potassium phosphate buffer pH 7.2 and 
incubated with/without 50 µM of EGCG for 24 
hours. The flouresence intensities were 
recorded and expressed as arbitrary unit (A.U.) 
at the time intervals given on the figure. ThT 
fluorescences were obtained using 8 μM ThT in 
100 mM sodium phosphate buffer, pH 7.4, by 
spectrofluorometer (Shimadzu RF-5301, 
Japan) at wavelengths Ex: 442 and Em: 482. 































In order to estimate the probable inhibitory 
effect of EGCG on cholinesterase activities and 
perform further kinetic evaluation, IC50 values 
were determined as 55 ± 1,3 µM for AChE and 
63 ± 1,1 µM for BChE.  Inhibitor types and 
kinetic properties for both enzymes were 
determined by Lineweaver-Burk plots with 
secondary reciprocals. As shown in Figure 1 the 
inhibition of AChE by EGCG was 
uncompetitive (Figure 1).   
EGCG inhibited BChE in a dose related 
manner.  The inhibition type was uncompetitive 




























   
 
Figure 1. The Lineweaver-Burke (A) and reciprocal (B) plot of AChE inhibition by EGCG. Each point is the 
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whereas at high inhibitor concentrations 
(75,100 µM) inhibition was   noncompetitive 
(Figure 2). The reciprocal plots for each are 
given respectively in Figure 3 A and B. 
The types of inhibitions and inhibitor-enzyme 
dissociation constant (Ki) values were given in 
Table 1.  
Amyloid Destabilization 

































of fibrillation (1-40-140, 1-42-1-42 and 1-40-
42) was tested with the Tht fluorescence 
method.  As shown in Figure 4 EGCG inhibited 
the formation of all types of fibril aggregation 
from the fourth hour of experiment. Rifampicin 
which is a well-known standard destabilizing 



































   
Figure 3. The reciprocal plots for (A) uncompetetive (B) noncompetetive inhbition of BChE   inhibition by 






























Table 1. The kinetic data of inhibitory parameters of EGCG on cholinesterases. Values are expressed 
as mean ± SEM. 
Enzyme  Inhibition type Ki (mM) 
AChE Uncompetitive 222.3 ±1.25 
BChE  
25-50 mM EGCG   
75-100 mM EGCG 
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In our study EGCG is found to inhibit both 
types of cholinesterases and also amyloid 
aggregation. Although the calculated IC50’s 
were not promising when compared to the 
values of donepezil (23.1 nM for human 
recombinant AChE and and 7.4 nM for BChE) 
the discovery of dual inhibiory effect was 
satisfactory [17]. 
The plots indicated an uncompetetive inhibition 
of AChE and a dose related inhibition pattern 
for BChE. 
Due to its physiological importance, AChE is 
one of the most investigated enzymes for the in 
vivo and in vitro effects of herbal medicines. 
There are several reports indicating the roles of 
ginsenosides [18], flavanoids [19], and other 
types of plant-based sources on the activity of 
cholinesterases. 
The active site of cholinesterases (active gorge) 
has five different regions for proper catalysis. 
The amino acid content of these sites differ for 
AChE and BChE and contribute to the 
differences in catalytic activites and their 
behavior against the inhibitors. It is mainly 
known that the gorge of AChE is smaller than 
the active gorge of BChE by the replacement of 
14 aromatic amino acids with the aliphatic ones. 
The common catalytic site is a catalytic triad 
having Ser-His-Glu residues [20].   
In our model, the uncompetitive inhibition of 
AChE indicates an interaction of EGCG with a 
site other than the catalytic triad of the enzyme. 
The smaller gorge of AChE may block the 
entrance of EGCG to active site and EGCG is 
captured by the PAS. The peripheral anionic 
site (PAS) which is placed on the entry of active 
gorge has Asp and Tyr amino acids. EGCG is a 
polyphenolic substance having free hydroxyl 
residues in its structure. Due to the probable 
hydrogen bond formation between Asp/Tyr 
amino acids with these polyhydroxyls an 
uncompetitive inhibition is caused by EGCG 
[21]. 
The inhibition of BChE with EGCG showed an 
interesting pattern. At concentrations below 
IC50 values the inhibition was uncompetitive 
whereas noncompetitive inhibition was 
observed at concentrations greater than 50 µM. 
These results implied a multi-site interaction of 
molecule with the enzyme. In order to prove our 
assumption Hill plot was constructed [22]. By 
the plot, inhibitor binding sites were calculated 
as 1.9 and 2.4 at low and high concentrations 
respectively having an average 2.15. The n 
values greater than 1 obtained by Hill plot 
indicates more than one binding sites for 
inhibitor – enzyme relationship and this data 
clarified dose related inhibition pattern. Also 
findings were in accordance with the previous 
studies dealing with this type of inhibitions 
[17,23]. This observation is generally reported 
due to   conformational change at the active site 
of BChE by increasing concentrations of 
inhibitor. Several reports mention the 
importance of Leu and Val residues of acyl 
bonding pocket of BChE for the binding of 
large molecules [24,25]. We postulate that this 
change of inhibition type is caused by the 
binding of EGCG to PAS at low concentrations 
and the increased concentrations predominating 
interaction with the second site, acyl pocket.  
EGCG also inhibited the amyloid fibril 
aggregation in a time course manner. Previous 
studies report [26] the destabilizing effect of 
EGCG on Ab42 fibrillation but we investigated 
all types of fibrillation processes. All types of 
fibril formations was observed to increase by 
the two hours of experiment and EGCG 
destabilized the fibrillation from fourth hours. 
Rifampicin which is a well- accepted 
fibrillation destabilizer inhibited fibril 
formation by 90.9% in 24 h and EGCG is 
inhibited only by 7%. The selected 
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concentration of EGCG was only 50 µM in 
order to sustain and mimic IC50 levels and we 
conclude that the fibrillation inhibitions may be 
repeated in dose dependent manner. 
 
Conclusion 
The dual inhibitory effect on both 
cholinesterases and amyloidogenesis is a well 
investigated effect of molecules for the 
treatment of AD and depending on this 
approach our findings add a new insight to 
known beneficial effects of EGCG on 
neurodegenerative diseases.  
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